Jang Ryul Park

Title: Jang Ryul Park: Innovator in Anti-Angiopoietin-2 Antibodies

Introduction

Jang Ryul Park is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies that target angiopoietin-2. With a total of 3 patents to his name, his work has the potential to impact various medical treatments.

Latest Patents

One of his latest patents focuses on anti-angiopoietin-2 antibodies that induce Tie2 activation. This invention relates to mouse antibodies that bind to angiopoietin-2 (Ang2) and includes humanized anti-Ang2 antibodies derived from them. The anti-Ang2 antibodies serve a dual purpose by activating the Tie2 receptor while neutralizing Ang2. These antibodies have shown the ability to normalize abnormal and pathological blood vessels, demonstrating therapeutic efficacy against diseases associated with such conditions. Furthermore, the invention provides an angiogenesis inhibitor and a composition for treating diseases linked to abnormal Ang2 expression and Tie2 dysregulation, which includes the antibody as an active ingredient.

Career Highlights

Jang Ryul Park has worked at prestigious institutions such as the Korea Advanced Institute of Science and Technology and the Institute for Basic Science. His research has contributed to advancements in understanding and treating vascular-related diseases.

Collaborations

Some of his notable coworkers include Wangyuhl Oh and Gou Young Koh. Their collaborative efforts have likely enhanced the research and development of innovative solutions in the field.

Conclusion

Jang Ryul Park's work in developing anti-angiopoietin-2 antibodies represents a significant advancement in biotechnology. His contributions have the potential to lead to new therapeutic options for patients suffering from diseases related to abnormal blood vessels.